Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up - Kreitman, R. J., Tallman, M. S., Robak, T., Coutre, S., Wilson, W. H., Stetler-Stevenson, M., Fitz; Gerald, D. J., Santiago, L., Gao, G., Lanasa, M. C., Pastan, I. (American Society of Hematology (ASH), 2018)
6266229